Clinical-stage biotechnology company Viking Therapeutics (VKTX) has seen its stock edge slightly lower year-to-date, but multiple key catalysts over the next 12 months could drive substantial upside. Several Wall Street analysts are highly optimistic about its prospects. For instance, Cantor Fitzgerald analyst Steven Seedhouse has set a $100 price target, implying the stock could triple from current levels. Oppenheimer’s Jay Olson and HC Wainwright’s Joseph Pantginis have also issued similar target prices.
Viking’s lead candidate, VK2735, is being developed for obesity indications. Its subcutaneous injection formulation has already initiated Phase III studies, while the oral formulation is expected to enter late-stage trials before the end of the year. Top-line results from the subcutaneous Phase III program are anticipated in the second half of next year. The market clearly expects positive data, but how strong must the results be to support a doubling or more in the stock price? In the 13-week Phase II study, VK2735 achieved a mean weight loss of 14.7%. With the Phase III study extending to 78 weeks, the market’s expected figure will be significantly higher. If Phase III data only show approximately 15% mean weight loss, it would greatly disappoint investors, particularly for a non-diabetic population. Currently, the best-in-class benchmark in the industry is Eli Lilly’s retatrutide, which delivered 28.3% mean weight loss over 80 weeks in its Phase III trial—the top performance among peers. Theoretically, VK2735 could surpass that level, but given that no other weight-loss drug has come close to that figure, and retatrutide’s unique mechanism of action plausibly explains its superior results, investors should not bank on such an outcome. A more realistic “surprise range” for the market likely falls between 23% and 26% mean weight loss. If results approach the upper end of that range, the stock could see a significant near-term rally.
Assuming VK2735 achieves 26% weight loss, Viking’s current $4 billion market capitalization could rise to $12 billion by the end of next year. Extending that further, assume the company could generate $4 billion in annual sales by 2032 (feasible at that efficacy level) and assign a 5x price-to-sales multiple (reasonable for the biotech sector), the market cap would then reach $20 billion, corresponding to a five-year compound annual growth rate of approximately 10.8% starting in 2027. However, this optimistic scenario does not yet account for potential safety and tolerability issues that may emerge in the Phase III data. The company is also conducting separate dose-ranging studies of VK2735 for weight maintenance, with data expected before year-end. If both the maintenance study and the Phase III results are outstanding, they could indeed drive a sharp rally in the stock—but that would require near-perfect data, and investors should not bet on that outcome.
Viking Therapeutics’ VK2735 is highly competitive in the rapidly growing weight-loss drug market. The drug is a GLP-1/GIP dual receptor agonist, belonging to the same class as the current blockbuster Zepbound, and the development of an oral formulation could further enhance its competitiveness—recently launched oral weight-loss drugs have already demonstrated strong market acceptance. However, any clinical setback in the core pipeline would severely hammer the stock, and recovery would be difficult and slow. Therefore, the stock is extremely volatile and suitable only for investors who fully understand the risks and can tolerate sharp fluctuations, with consideration for only a modest allocation.
Summary: Viking Therapeutics possesses a promising weight-loss pipeline with concentrated near-term catalysts. If Phase III data fall within the 23%-26% weight-loss range, the stock has theoretical potential for significant upside. But this scenario rests on multiple perfect assumptions; in reality, any blemish in safety or efficacy data could reverse the trend. This stock is a quintessential high-risk, high-volatility name, and investors must carefully assess their own risk tolerance before making any decisions.
